Showing results (151-160 of 163) with videos related to
Sort By:
Pageof 17
Neuro-Oncology|October 28, 2017
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastomaHui K Gan, David A Reardon, Andrew B Lassman, et al.JAMA Oncology|February 18, 2021
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical TrialOtto Metzger Filho, Daniel G Stover, Sarah Asad, et al.Gynecologic Oncology|December 15, 2021
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 studyElizabeth M Swisher, Carol Aghajanian, David M O'Malley, et al.Journal of Neuro-Oncology|July 6, 2019
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastomaAndrew B Lassman, Kenneth D Aldape, Peter J Ansell, et al.NPJ Breast Cancer|November 12, 2021
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightnessOtto Metzger-Filho, Katharine Collier, Sarah Asad, et al.Cancer|March 14, 2018
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptorGlenwood D Goss, Everett E Vokes, Michael S Gordon, et al.Regulatory Toxicology and Pharmacology : RTP|August 14, 2021
Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredientsM P Dent, E Vaillancourt, R S Thomas, et al.Trials|September 17, 2016
Hughes Abdominal Repair Trial (HART) - Abdominal wall closure techniques to reduce the incidence of incisional hernias: study protocol for a randomised controlled trialJ Cornish, R L Harries, D Bosanquet, et al.Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.Neuro-Oncology|July 9, 2018
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trialAndrew B Lassman, Martin J van den Bent, Hui K Gan, et al.Pageof 17